<p>New findings show that the medication known as Wegovy® (semaglutide) can reduce existing heart disease in patients with obesity by 20%, according to a study co-authored by past presidents of The Obesity Society and published in <em>The</em> <em>New England Journal of Medicine</em>.</p>
Besides prioritizing a nutritionally balanced eating plan, such as a Mediterranean diet, guidelines for type 2 diabetes should also recommend limiting ultraprocessed foods, say researchers in Italy.
CagriSema (cagrilintide plus semaglutide) led to weight loss of a magnitude not previously reported with pharmacotherapies in type 2 diabetes, plus improved CGM measures, in a phase 2 trial.
Newer weight loss drugs are useful tools for patients with obesity, including those who have had bariatric surgery. But debate continues as to how long people should stay on them.